TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30326947
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound therapy (in pilot subset)
Study: 30326947
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (in pilot subset)
Study: 27517053
Drug: ArmeoSpring training
Approvals — FDA: no, EMA: no, PMDA: no
Description: ArmeoSpring training for 45 minutes daily, 5 days per week for 3 weeks, in addition to conventional rehabilitation
Study: 22218156
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training with fish oil supplementation (ST90 group) for 90 days (2 g/d)
Study: 22218156
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training with fish oil supplementation (ST150 group) for 150 days (2 g/d, supplemented 60 days before training)
Study: 20932341
Drug: Intra-articular BMP-7
Normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intra-articular BMP-7 (1 mg)
Study: 20932341
Drug: Intra-articular BMP-7
Normalized name: BMP-7
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intra-articular BMP-7 (0.1 mg and 0.3 mg)
Study: 8592597
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg DFO test
Study: 8592597
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg DFO test
Study: 8592597
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg DFO test for detecting aluminium toxicity
Study: 8592597
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg DFO test for detecting aluminium toxicity
Study: 8592597
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg DFO test for detecting aluminium overload
Study: 8592597
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg DFO test for detecting aluminium overload
Study: 30611752
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (6 mg/kg of body-mass)
Study: 24252360
Drug: Olaparib, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib, 400 mg orally twice daily until disease progression or drug intolerance
Study: 22999717
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (12‐month DAPT), n=1058
Study: 17978849
Drug: Nonsterile gel
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsterile gel
Study: 12407043
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg on days 2-6
Study: 12407043
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg on days 5-9
Study: 10428533
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (n = 17)
Study: 1730330
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) deslorelin, 300 micrograms daily for 4 months
Study: 29768149
Drug: Budesonide-formoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed
Study: 29768149
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg) used as needed
Study: 29768149
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 μg) plus terbutaline used as needed
Study: 22949154
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg per day
Study: 21129474
Drug: Topical Tangzu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tangzu Yuyang Ointment (TYO) plus standard wound therapy (SWT)
Study: 17452166
Drug: Controlled-release paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release paroxetine
Study: 9510396
Drug: Interferon-alpha (IFNalpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFNalpha) therapy
Study: 7357809
Drug: Nefopam 45
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 45 mg
Study: 359216
Drug: Nefopam 90
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 90 mg
Study: 6973987
Drug: Propoxyphene 65
Normalized name: propoxyphene hydrochloride 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene 65 mg
Study: 31922998
Drug: Nephrotoxic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrotoxic drugs discontinuation
Study: 31922998
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of radiocontrast agents
Study: 28329211
Drug: GEN‐003 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN‐003 (30 µg)
Study: 28329211
Drug: GEN‐003 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN‐003 (100 µg)
Study: 28329211
Drug: GEN‐003 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN‐003 (10 µg)
Study: 21209231
Drug: Sitagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 200 mg/day (2 × 100 mg tablets)
Study: 19216606
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution (2%)
Study: 19216606
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (1%)
Study: 19216606
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no chlorhexidine treatment)
Study: 17944273
Drug: Inhaled ribavirin
Normalized name: ribavirin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ribavirin
Study: 17944273
Drug: Promising new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promising new agents
Study: 11574372
Drug: Levobupivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Study: 11574372
Drug: Racemic bupivacaine
Normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic bupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Study: 9634262
Drug: Steam-distilled garlic
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam-distilled garlic oil preparation (5 mg twice a day)
Study: 7945742
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications with a placebo run-in period
Study: 7945742
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications with a post-randomization placebo treatment cell
Study: 1968233
Drug: Idazoxan (alpha‐2‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (alpha‐2‐adrenoceptor antagonist)
Study: 1968233
Drug: Idazoxan and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan and naloxone combination
Study: 30811963
Drug: Lorcaserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (10 mg)
Study: 28011247
Drug: Nebulized arformoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized arformoterol 15 µg BID
Study: 23382470
Drug: Corticorelin acetate
Normalized name: Corticorelin acetate
DrugBank: Corticorelin acetate (DB12915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticorelin acetate (CrA) 1 mg twice per day
Study: 21269553
Drug: Epley's manoeuvre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epley's manoeuvre plus labyrinthine sedative
Study: 19167712
Drug: Atorvastatin 80mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80mg/d
Study: 19167712
Drug: Atorvastatin 10mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10mg/d
Study: 15502038
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg mivacurium (MV group, n = 10)
Study: 15502038
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg pancuronium (PC group, n = 10)
Study: 10661294
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support with enriched food supplements
Study: 29813097
Drug: B‐vitamins alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐vitamins alone (560 μg of 5‐methyl‐THF, 3 mg of vitamin B6 and 20 μg of vitamin B12)
Study: 29813097
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio)
Study: 27578110
Drug: DHA-enriched fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched fish oil (2.4 g per day for 8 weeks)
Study: 8792890
Drug: Lidocaine aerosol
Normalized name: Lidocaine Topical Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine aerosol 500 mg (100 mg/ml; Xylocain aerosol, ASTRA, Sweden)
Study: 6398021
Drug: Immunosuppressive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drug therapy with plasmapheresis (PP)
Study: 30941124
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell therapy targeting HLA‐A02 restricted HIV antigen epitopes
Study: 17568252
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of daily 6x15 min ergometer training at submaximal intensity plus 1 h/week group exercise session followed by 5 months of home-based ergometer training of 30 min/day plus 1 h/week group exercise session
Study: 12062596
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (vinblastine 5 mg/m(2) i.v. bolus weekly for the first 5 weeks, and cisplatin, 100 mg/m(2) i.v. on Days 1 and 29) followed by concurrent chemotherapy/radiotherapy (cisplatin 75 mg/m(2) i.v. on Days 50, 71, and 92) during thoracic radiotherapy (63 Gy in 34 fractions during 7 weeks starting on Day 50)
Study: 12062596
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and hyperfractionated radiotherapy starting on Day 1 with a total dose of 69.6 Gy in 58 fractions during 6 weeks, 1.2 Gy/fraction b.i.d. (cisplatin, 50 mg/m(2) i.v. on Days 1 and 8, and oral VP‐16, 50 mg b.i.d. for 10 days only on the days of thoracic radiotherapy repeated on Day 29)
Study: 9593141
Drug: sorivudine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorivudine (40 mg once daily)
Study: 9593141
Drug: acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir (800 mg five times daily)
Study: 278688
Drug: Toothbrush with
Normalized name: Suction Toothbrush with Corinz Oral Rinse KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothbrush with supervised oral cleaning
Study: 278688
Drug: Mefaka (chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefaka (chewing stick) with supervised oral cleaning
Study: 31301476
Drug: Self-guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided internet-delivered cognitive behavior therapy (ICBT)
Study: 26094635
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous microwave ablation with ethanol injection
Study: 26094635
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous microwave ablation without ethanol injection (control group)
Study: 23489301
Drug: Alogliptin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5 and 25 mg daily)
Study: 23489301
Drug: Comparator therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator therapies (other antidiabetic agents)
Study: 19114436
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy for 12 months
Study: 11416883
Drug: Intravenous BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous BH4 (10 mg/kg)
Study: 9595286
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/day for 16 weeks)
Study: 7801667
Drug: molsidomine 8
Normalized name: molsidomine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine 8 mg bid
Study: 3050654
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg twice daily for 7 days
Study: 1754753
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg twice daily for 7 days
Study: 30665513
Drug: Supervised ground-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised ground-based walking training (30–45 min, 2–3 times weekly for 8–10 weeks)
Study: 25945012
Drug: PDN+MTD 500
Normalized name: IL-2 pDNA
DrugBank: IL-2 pDNA (DB05935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDN+MTD 500 mg three times daily
Study: 25945012
Drug: PTX+MTD 500
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX+MTD 500 mg three times daily
Study: 21285094
Drug: Collaborative model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative model of depression care (problem-solving therapy, antidepressants, symptom monitoring, and relapse prevention)
Study: 19920418
Drug: Double-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection technique
Study: 19920418
Drug: Single-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection technique
Study: 17899571
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (90 mg daily)
Study: 3514833
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (750 IU daily from 2nd week of life)
Study: 31515152
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy (HFOT)
Study: 25762401
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with free-saline solution
Study: 18634501
Drug: One intradermal
Normalized name: Fluzone Intradermal 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intradermal injection of 0.1 ml (1 site) followed by two booster vaccinations of 0.1 ml (1 site) intradermally on days 0 and 3
Study: 18634501
Drug: Three intradermal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intradermal injections within one week
Study: 18634501
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections administered over 3-4 weeks with two booster vaccinations on days 0 and 3 one year later
Study: 16060244
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (craniotomy or endovascular coil embolization)
Study: 16060244
Drug: Natural course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural course observation (no surgical treatment)
Study: 30008589
Drug: LdT (telbivudine)
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LdT (telbivudine) treatment
Study: 30008589
Drug: Observation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation group (no antiviral therapy)
Study: 27779639
Drug: Light exercise
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light exercise program (2-hour education session, five weekly 90-minute exercise training sessions, and home-based self-managed exercise program)
Study: 25532087
Drug: PCEA (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (bolus - 5 ml, lockout interval - 15 minutes, basal rate - 0 ml) with bupivacaine 0.08% and fentanyl 2 µg/ml
Study: 25532087
Drug: CEA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA (10 ml/h) with bupivacaine 0.08% and fentanyl 2 µg/ml
Study: 19584823
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (controls), n=86
Study: 17081656
Drug: 6 isoenergetic
Normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 isoenergetic meals fed hourly
Study: 15604943
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of milk
Study: 15604943
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of milk plus water
Study: 1782715
Drug: Topical antibiotic/steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotic/steroid mixture with alternate day dressings
Study: 1782715
Drug: Topical antibiotic/steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotic/steroid mixture with sump filling
Study: 6168426
Drug: MOP (the
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOP (the same combination without prednisone)
Study: 6168426
Drug: B‐MOPP (MOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐MOPP (MOPP plus bleomycin at low dosage)
Study: 6168426
Drug: CVB combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVB combination (CCNU, vinblastine and bleomycin)
Study: 19034466
Drug: Anterolateral (A-L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterolateral (A-L) trans-tibia approach
Study: 18089334
Drug: Valganciclovir oral
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir oral solution (900 mg)
Study: 18089334
Drug: Valganciclovir tablets
Normalized name: Valganciclovir Tablets
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir tablets (900 mg)
Study: 18089334
Drug: Valganciclovir oral
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir oral solution
Study: 18089334
Drug: Valganciclovir tablets
Normalized name: Valganciclovir Tablets
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir tablets
Study: 18089334
Drug: Valganciclovir oral
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir oral solution vs tablets
Study: 18089334
Drug: Valganciclovir oral
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir oral solution and tablets
Study: 8791950
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. (cohort A)
Study: 8791950
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., tetracycline 300 mg b.d. (cohort B)
Study: 6209488
Drug: Nicardipine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 5 mg i.v.
Study: 6209488
Drug: Nicardipine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 10 mg i.v.
Study: 6209488
Drug: Nicardipine 2.5
Normalized name: niCARdipine 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2.5 mg i.v. after beta-blockade with propranolol
Study: 31180258
Drug: FCL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL plus topical SC‐CM
Study: 31180258
Drug: FCL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCL plus topical PRP
Study: 27302306
Drug: Supportive-expressive discussion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive discussion groups (12 weekly 90-min sessions)
Study: 25419597
Drug: Low-dose oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose oral, delayed-release mesalamine (27-71 mg · g(‐1) · day(‐1))
Study: 25419597
Drug: High-dose oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral, delayed-release mesalamine (53-118 mg · g(‐1) · day(‐1))
Study: 25419597
Drug: Low-dose oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose oral, delayed-release mesalamine
Study: 25419597
Drug: High-dose oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral, delayed-release mesalamine
Study: 18379511
Drug: Hydroxyzine (atarax)
Normalized name: hydroxyzine hydrochloride Oral Solution [Atarax]
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine (atarax) as a substitutive therapy after immediate withdrawal of BDT
Study: 18379511
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy during continuous withdrawal of BDT over 14 days
Study: 10385768
Drug: Intravenous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous continuous dobutamine
Study: 26293185
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of autogenous and xenogenous bone for conventional sinus floor augmentation
Study: 7651682
Drug: Alkalinized anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkalinized anesthetic solution
Study: 7651682
Drug: Nadbath injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadbath injection
Study: 3046631
Drug: Dilevalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200 mg)
Study: 349379
Drug: Concurrent quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent quality assurance (CQA)
Study: 31712214
Drug: RV521 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV521 350 mg
Study: 31712214
Drug: RV521 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV521 200 mg
Study: 28727702
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of triamcinolone and lidocaine
Study: 23698171
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) by dentists